NTHI
Neonc Technologies Holdings
NASDAQ · Pharmaceuticals
$9.77
+0.53 (+5.74%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 43.67M | 45.52M | 48.53M |
| Net Income | 9.08M | 8.50M | 8.83M |
| EPS | — | — | — |
| Profit Margin | 20.8% | 18.7% | 18.2% |
| Rev Growth | -7.1% | -1.4% | +12.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 13.21M | 13.53M | 15.66M |
| Total Equity | 166.04M | 174.37M | 161.35M |
| D/E Ratio | 0.08 | 0.08 | 0.10 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 14.45M | 13.90M | 17.76M |
| Free Cash Flow | 12.29M | 13.27M | 13.39M |